Csenge Advisory Group’s Avanos Medical AVNS Stock Holding History

Csenge Advisory Group’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11	Closed	–	–	303
2018 Q3	$0	Buy	+11	New	+$708	﹤0.01%	1058

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Csenge Advisory Group's AVNS Position: Q4 2018 in Review

Csenge Advisory Group sold out of Avanos Medical (AVNS) in Q4 2018, closing a stake of 11 shares.

Csenge Advisory Group first reported a position in AVNS in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 350 funds tracked by Wall St. Rank hold AVNS as of Q4 2018.

Csenge Advisory Group reported no remaining Avanos Medical position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 11 Avanos Medical shares in Q4 2018.
Csenge Advisory Group first reported a position in Avanos Medical in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Avanos Medical position peaked at $0 in Q3 2018.
350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.